- Myokardia’s Phase 3 trial for Mavacamten will read out in 2020.
- Amgen & Cytokinetics' omecamtiv mecarbil as they continue development with the GALACTIC-HF trial
- Entresto has reported positive results from a mid-stage safety study, which will be reviewed.
Looking into the Chronic Heart Failure Market with a review of: Myokardia’s Mavacamten program, Amgen & Cytokinetics' omecamtiv mecarbil as they continue development with the GALACTIC-HF trial, and Novartis' Entresto.Ticker(s): MYOK, AMGN, CYTK, NVS
A cardiologist with a focus on patients with Hypertrophic Cardiomyopathy and familiarity with the drugs in development.
133Days Left to Join Project
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.